Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)

Abstract

The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immuno-compromised. Compositions are provided that inhibit intracellular replication of DNA viruses.

1 - 42 . (canceled) 
     
     
         43 . A method comprising administering a composition comprising fusidic acid to a subject before, during or after the subject receives an immunomodulatory therapy for a disease or condition. 
     
     
         44 . The method of  claim 43 , wherein the composition is administered to the subject during the immunomodulatory therapy. 
     
     
         45 . The method of  claim 43 , wherein the composition is administered to the subject before the immunomodulatory therapy. 
     
     
         46 . The method of  claim 43 , wherein the subject is known to have been exposed to a polyomavirus infection. 
     
     
         47 . The method of  claim 46 , wherein the subject is identified as having been exposed to a polyomavirus infection by detecting one or more serum antibodies against a polyomavirus molecule or by detecting one or more polyomavirus molecules obtained from the subject. 
     
     
         48 . The method of  claim 46 , wherein the polyomavirus is JC virus or BK virus. 
     
     
         49 . The method of  claim 46 , wherein the subject has a polyomavirus infection. 
     
     
         50 . The method of  claim 43 , wherein the disease or condition is multiple sclerosis, rheumatoid arthritis, myasthenia gravis, systemic lupus erythematosus or an inflammatory bowel disease or syndrome. 
     
     
         51 . The method of  claim 50 , wherein the disease or condition is multiple sclerosis. 
     
     
         52 . The method of  claim 50 , wherein the disease or condition is Crohn's disease. 
     
     
         53 . The method of  claim 43 , wherein the immunomodulatory therapy comprises administration of a VLA-4 antibody. 
     
     
         54 . The method of  claim 53 , wherein the VLA-4 antibody is natalizumab. 
     
     
         55 . A method comprising administering a composition comprising fusidic acid to a subject who has a weakened immune system. 
     
     
         56 . The method of  claim 55 , wherein the subject has a polyomavirus infection. 
     
     
         57 . The method of  claim 56 , wherein the polyomavirus is JC virus or BK virus. 
     
     
         58 . A method comprising administering a composition comprising fusidic acid to a subject having multiple sclerosis, wherein the composition is administered to the subject before, during or after the subject receives an immunomodulatory therapy for multiple sclerosis. 
     
     
         59 . The method of  claim 58 , wherein the subject has a JC virus infection or a BK virus infection. 
     
     
         60 . The method of  claim 58 , wherein the immunomodulatory therapy comprises the administration of a VLA-4 antibody. 
     
     
         61 . The method of  claim 60 , wherein the VLA-4 antibody is natalizumab.